Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year

Contraception

Volumn 93, Issue 3, 2016, Pages 263-265

  Morrell, Kathleen M ^a   Cremers, Serge ^a   Westhoff, Carolyn L ^a   Davis, Anne R ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Contraception; Etonogestrel; Implant; Obesity

Indexed keywords

CONTRACEPTIVE AGENT; ETONOGESTREL; GESTAGEN; DESOGESTREL; DRUG IMPLANT;

ADULT; ARTICLE; BLOOD SAMPLING; BODY COMPOSITION; BODY MASS; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMMUNITY SAMPLE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DRUG IMPLANT; ETONOGESTREL IMPLANT; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; OBESITY; PREGNANCY; ADOLESCENT; BLOOD; OVULATION INHIBITION; YOUNG ADULT;

ADOLESCENT; ADULT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DESOGESTREL; DRUG IMPLANTS; FEMALE; HUMANS; OBESITY; OVULATION INHIBITION; YOUNG ADULT;

EID: 84958811475     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2015.11.005     Document Type: Article

References (12)

1. C.L. Ogden, M.D. Carroll, B.K. Kit, and K.M. Flegal Prevalence of childhood and adult obesity in the United States, 2011-2012 JAMA 311 8 2014 806 814 10.1001/jama.2014.732
2. Merck & Co., Inc Nexplanon prescribing information Accessed September 3, 2015 at http://www.merck.com/product/usa/pi-circulars/n/nexplanon/nexplanon-pi.pdf 2015
3. H.B. Croxatto, and L. Mäkäräinen The pharmacodynamics and efficacy of Implanon® Contraception 58 1998 91S 97S
4. G. Cheymol Effects of obesity on pharmacokinetics: implications for drug therapy Clin Pharmacokinet 39 3 2000 215 231
5. C. Ciangura, N. Corigliano, A. Basdevant, S. Mouly, X. Declèves, P. Touraine, and et al. Etonogestrel concentrations in morbidly obese women following Roux-en-Y gastric bypass surgery: three case reports Contraception 84 2011 649 651 10.1016/j.contraception.2011.03.015
6. S. Mornar, L.N. Chan, S. Mistretta, A. Neustadt, S. Martins, and M. Gilliam Pharmacokinetics of the etonogestrel contraceptive implant in obese women Am J Obstet Gynecol 207 2 2012 110.e1 110.e6 10.1016/j.ajog.2012.05.002
7. C. McNicholas, R. Maddipati, Q. Zhao, E. Swor, and J.F. Peipert Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration Obstet Gynecol 125 3 2015 599 604 10.1097/AOG.0000000000000690
8. S. Díaz, M. Pavez, A.J. Moo-Young, C.W. Bardin, and H.B. Croxatto Clinical trial with 3-keto-desogestrel subdermal implants Contraception 44 4 1991 393 408
9. T. Thomas, K. Petrie, J. Shim, K.M. Abildskov, C.L. Westhoff, and S. Cremers A UPLC-MS/MS method for therapeutic drug monitoring of etonogestrel Ther Drug Monit 35 6 2013 844 848 10.1097/FTD.0b013e31829a10fa
10. C.J. Timmer, and T.M. Mulders Pharmacokinetics of etonogestrel and ethinyl estradiol released from a combined contraceptive vaginal ring Clin Pharmacokinet 39 2000 233 242
11. H. Xu, J.A. Wade, J.F. Peipert, Q. Zhao, T. Madden, and G.M. Secura Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women Obstet Gynecol 120 1 2012 21 26 10.1097/AOG.0b013e318259565a
12. C.L. Westhoff, A.H. Torgal, E.R. Mayeda, K. Petrie, T. Thomas, M. Dragoman, and et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women Am J Obstet Gynecol 207 1 2012 39.e1 39.e6 10.1016/j.ajog.2012.04.022